Kantor O - Search Results

1

Screening MRI Does Not Increase Cancer Detection or Result in an Earlier Stage at Diagnosis for Patients with High-Risk Breast Lesions: A Propensity Score Analysis.

Laws A, Katlin F, Hans M, Graichen M, Kantor O, Minami C, Bychkovsky BL, Pace LE, Scheib R, Garber JE, King TA. Laws A, et al. Among authors: kantor o. Ann Surg Oncol. 2023 Jan;30(1):68-77. doi: 10.1245/s10434-022-12568-z. Epub 2022 Sep 28. Ann Surg Oncol. 2023. PMID: 36171529

2

Clinical accuracy of preoperative breast MRI for breast cancer.

Tseng J, Kyrillos A, Liederbach E, Spear GG, Ecanow J, Wang CH, Czechura T, Kantor O, Miller M, Winchester DJ, Pesce CE, Rabbitt S, Yao K. Tseng J, et al. Among authors: kantor o. J Surg Oncol. 2017 Jun;115(8):924-931. doi: 10.1002/jso.24616. Epub 2017 Apr 13. J Surg Oncol. 2017. PMID: 28409837

3

The Impact of Facility Volume on Rates of Pathologic Complete Response to Neoadjuvant Chemotherapy Used in Breast Cancer.

Ajmani GS, James TA, Kantor O, Wang CH, Yao KA. Ajmani GS, et al. Among authors: kantor o. Ann Surg Oncol. 2017 Oct;24(11):3157-3166. doi: 10.1245/s10434-017-5969-1. Epub 2017 Jul 6. Ann Surg Oncol. 2017. PMID: 28685357

4

A Predictive Model for Axillary Node Pathologic Complete Response after Neoadjuvant Chemotherapy for Breast Cancer.

Kantor O, Sipsy LM, Yao K, James TA. Kantor O, et al. Ann Surg Oncol. 2018 May;25(5):1304-1311. doi: 10.1245/s10434-018-6345-5. Epub 2018 Jan 24. Ann Surg Oncol. 2018. PMID: 29368152

5

Comparative Analysis of Proposed Strategies for Incorporating Biologic Factors into Breast Cancer Staging.

Kantor O, Niu J, Zhao H, Giordano SH, Hunt KK, King TA, Mittendorf EA, Chavez-MacGregor M. Kantor O, et al. Ann Surg Oncol. 2020 Jul;27(7):2229-2237. doi: 10.1245/s10434-019-08169-y. Epub 2020 Jan 8. Ann Surg Oncol. 2020. PMID: 31916091

6

Baseline Screening MRI Uptake and Findings in Women with ≥ 20% Lifetime Risk of Breast Cancer.

Laws A, Mulvey TM, Jalbert N, Dalton S, Kantor O, Harris KA, Krag KJ, Walsh EP, Coopey SB. Laws A, et al. Among authors: kantor o. Ann Surg Oncol. 2020 Oct;27(10):3595-3602. doi: 10.1245/s10434-020-08853-4. Epub 2020 Jul 18. Ann Surg Oncol. 2020. PMID: 32683633

7

Node-Positive Patients Treated with Neoadjuvant Chemotherapy Can Be Spared Axillary Lymph Node Dissection with Wireless Non-Radioactive Localizers.

Laws A, Dillon K, Kelly BN, Kantor O, Hughes KS, Gadd MA, Smith BL, Lamb LR, Specht M. Laws A, et al. Among authors: kantor o. Ann Surg Oncol. 2020 Nov;27(12):4819-4827. doi: 10.1245/s10434-020-08902-y. Epub 2020 Aug 1. Ann Surg Oncol. 2020. PMID: 32740737

8

Association Between Time to Operation and Pathologic Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer.

Minami CA, Kantor O, Weiss A, Nakhlis F, King TA, Mittendorf EA. Minami CA, et al. Among authors: kantor o. J Am Coll Surg. 2020 Oct;231(4):434-447.e2. doi: 10.1016/j.jamcollsurg.2020.06.021. Epub 2020 Aug 6. J Am Coll Surg. 2020. PMID: 32771654 Free PMC article.

9

Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer.

Kantor O, Wong S, Weiss A, Metzger O, Mittendorf EA, King TA. Kantor O, et al. NPJ Breast Cancer. 2020 Aug 13;6:35. doi: 10.1038/s41523-020-00177-6. eCollection 2020. NPJ Breast Cancer. 2020. PMID: 32821803 Free PMC article.

10

Axillary Management After Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer.

Kantor O, Wakeman M, Weiss A, Wong S, Laws A, Grossmith S, Mittendorf EA, King TA. Kantor O, et al. Ann Surg Oncol. 2021 Mar;28(3):1358-1367. doi: 10.1245/s10434-020-09073-6. Epub 2020 Aug 31. Ann Surg Oncol. 2021. PMID: 32869154

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

128 results

Search Page

Filters